Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia

• Published in: Haematologica (Roma) Vol. 94; no. 2; pp. 280 - 284
• Main Authors: Lewintre, Eloisa Jantus, Martin, Cristina Reinoso, Ballesteros, Carlos Garcia, Montaner, David, Rivera, Rosa Farras, Mayans, Jose Ramon, Garcia-Conde, Javier
• Format: Journal Article
• Language: English
• Published: Pavia Ferrata Storti Foundation 01-02-2009
• Subjects: Biological and medical sciences; Biomarkers; Brief Reports; Cryptochromes; Flavoproteins - genetics; Hematologic and hematopoietic diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical sciences; Predictive Value of Tests; Prognosis; RNA, Messenger - analysis; Human; Heavy peptide chain; Immunoglobulins; Prognosis; Hematology; Variable region; Biological marker; B cell neoplasm; LPL; Malignant hemopathy; B-Lymphocyte; Cryptochrome-1; ZAP70; Chronic lymphocytic leukemia; IgVH; prognostic marker; Cancerology; Lymphoproliferative syndrome; Cryptochrome 1; Cancer
• ISSN: 0390-6078; 1592-8721
• DOI: 10.3324/haematol.13052

1 Molecular Haematology Laboratory, Prince Felipe Research Centre, Valencia
2 Haematology Department, Arnau de Vilanova Hospital, Valencia
3 Bioinformatic Department, Prince Felipe Research Centre, Valencia and
4 University of Valencia, Valencia, Spain
Correspondence: Eloisa Jantus Lewintre, PhD., Molecular Haematology Laboratory, Prince Felipe Research Centre, Avda Autopista El Saler 16-3, 46012, Valencia, Spain. E-mail: ejantus{at}cipf.es
Chronic lymphocytic leukemia is an adult-onset leukemia with a heterogeneous clinical behavior. When chronic lymphocytic leukemia cases were divided on the basis of IgV H mutational status, widely differing clinical courses were revealed. Since IgV H sequencing is difficult to perform in a routine diagnostic laboratory, finding a surrogate for IgV H mutational status seems an important priority. In the present study, we proposed the use of Cryptochrome-1 as a new prognostic marker in early-stage chronic lymphocytic leukemia. Seventy patients (Binet stage A, without treatment) were included in the study. We correlated Cryptochrome-1 mRNA with well established prognostic markers such as IgV H mutations, ZAP70, LPL or CD38 expression and chromosomal abnormalities. High Cryptochrome-1 expression correlated with IgV H unmutated samples. In addition, Cryptochrome-1 was a valuable predictor of disease progression in early-stage chronic lymphocytic leukemia, therefore it can be introduced in clinical practice with the advantage of a simplified method of quantification.
Key words: Cryptochrome-1, prognostic marker, chronic lymphocytic leukemia, ZAP70, LPL, IgV H .